Congress Asset Management Co. Increases Position in Insulet Co. (NASDAQ:PODD)

Congress Asset Management Co. lifted its stake in Insulet Co. (NASDAQ:PODD - Free Report) by 17.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 65,523 shares of the medical instruments supplier's stock after buying an additional 9,623 shares during the period. Congress Asset Management Co. owned approximately 0.09% of Insulet worth $17,106,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also made changes to their positions in the stock. Blue Trust Inc. boosted its position in shares of Insulet by 84.1% during the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier's stock worth $30,000 after acquiring an additional 58 shares in the last quarter. Venturi Wealth Management LLC lifted its stake in Insulet by 633.3% during the third quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier's stock worth $36,000 after purchasing an additional 133 shares during the last quarter. TD Private Client Wealth LLC boosted its holdings in shares of Insulet by 32.6% in the 3rd quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier's stock valued at $53,000 after purchasing an additional 56 shares in the last quarter. Friedenthal Financial bought a new position in shares of Insulet in the 4th quarter valued at $57,000. Finally, Versant Capital Management Inc raised its holdings in shares of Insulet by 106.1% during the 4th quarter. Versant Capital Management Inc now owns 305 shares of the medical instruments supplier's stock worth $80,000 after buying an additional 157 shares in the last quarter.

Insulet Trading Up 1.6 %

NASDAQ PODD traded up $4.61 during mid-day trading on Thursday, reaching $288.29. 849,879 shares of the stock were exchanged, compared to its average volume of 548,768. The stock has a market cap of $20.22 billion, a P/E ratio of 49.36, a P/E/G ratio of 3.52 and a beta of 1.23. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. Insulet Co. has a one year low of $160.19 and a one year high of $289.46. The stock has a 50 day simple moving average of $272.37 and a 200-day simple moving average of $246.18.

Insulet (NASDAQ:PODD - Get Free Report) last posted its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.00 by $0.15. Insulet had a return on equity of 27.98% and a net margin of 21.22%. On average, analysts anticipate that Insulet Co. will post 3.22 EPS for the current year.

Insiders Place Their Bets

In other news, CAO Lauren Budden sold 915 shares of the stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the transaction, the chief accounting officer now owns 5,733 shares of the company's stock, valued at $1,580,129.46. This represents a 13.76 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Eric Benjamin sold 12,394 shares of the firm's stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the sale, the executive vice president now owns 11,383 shares of the company's stock, valued at approximately $3,187,240. This represents a 52.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.47% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. Morgan Stanley raised their price objective on Insulet from $234.00 to $317.00 and gave the company an "overweight" rating in a research note on Monday, November 11th. Citigroup raised their price target on shares of Insulet from $283.00 to $310.00 and gave the company a "buy" rating in a research note on Wednesday, December 11th. Sanford C. Bernstein began coverage on shares of Insulet in a research report on Wednesday, November 6th. They set an "outperform" rating and a $300.00 price objective for the company. BTIG Research raised their target price on shares of Insulet from $260.00 to $270.00 and gave the company a "buy" rating in a research report on Friday, November 8th. Finally, Barclays boosted their target price on shares of Insulet from $220.00 to $234.00 and gave the stock an "equal weight" rating in a research note on Monday, November 11th. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $277.13.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.